Av. das Esmeraldas, 2899 - Jardim Tangara, Marília - SP
Email
recepcao@clinicasgarbi.com.br
Fale Conosco
(14) 3433-2423 / (14) 3433-0268 / (14) 98135-4871

Postado em 04/03/2021

Uma abordagem contemporânea prática para a tomada de decisão sobre hipotireoidismo subclínico!

Artigo escrito por: José Augusto Sgarbi, Laura Sterian Ward

Abstract

Subclinical hypothyroidism (Shypo) is an increasingly frequent condition in common medical practice. Its diagnosis continues to pose a challenge since a series of non-thyroidal and temporary conditions can elevate serum TSH levels. In addition, the consequences of Shypo are still up for debate. Although detrimental cardiovascular effects have been consistently demonstrated in the young, they are less evident in older adults (65-79 years), and even more so in the oldest old (≥80 years). In the absence of evidence of any benefits of treating Shypo in patients' clinical manifestations and unfavorable outcomes, the most effective decision-making approach should include a thorough investigation of the patient's condition integrating all relevant clinical data, such as TSH levels, age, quality of life, comorbidities, cardiovascular risk, safety, and personal preferences. The decision-making process needs to take into account the risk of levothyroxine overtreatment and the resulting adverse consequences, such as reduction of bone mineral density, heart failure, and atrial fibrillation. Hence, current evidence suggests that individuals with TSH > 10 mU/L, who test positive for TPO Ab or are symptomatic may benefit from levothyroxine treatment. However, a more cautious and conservative approach is required in older (≥65 years of age), and oldest-old (≥80 years) patients, particularly those with frailty, in which the risk of treatment can outweigh potential benefits. The latter may benefit from a wait-and-see approach.

Keywords: Subclinical hypothyroidism; levothyroxine; thyrotropin; treatment; update.

Copyright © 2018 Clinica Sgarbi. Todos os direitos reservados.

Desenvolvido por